Stock AELIS AELIS FARMA
Add to a list
To use this feature you must be a member
Log inSign up

Aelis Farma Share Price

Equities

AELIS

FR0014007ZB4

Pharmaceuticals

Real-time Euronext Paris
Other stock markets
 12:03:12 29/04/2024 BST 		5-day change 1st Jan Change
13.1 EUR +0.77% Intraday chart for Aelis Farma 0.00% 0.00%
04-18 Aelis Farma SA Announces the Last Patient, Last Visit in its Clinical Phase 2b Trial with AEF0117 for the Treatment of Cannabis Use Disorder CI
04-02 Aelis Farma SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2023 12.36M 13.25M 1.06B Sales 2024 * 54.03M 57.93M 4.62B Capitalization 171M 183M 14.59B
Net income 2023 -5M -5.36M -427M Net income 2024 * 33M 35.38M 2.82B EV / Sales 2023 13.9 x
Net cash position 2023 * 13.9M 14.9M 1.19B Net cash position 2024 * 117M 125M 9.96B EV / Sales 2024 * 1 x
P/E ratio 2023 *
-9.56 x
P/E ratio 2024 *
-7.14 x
Employees 22
Yield 2023 *
-
Yield 2024 *
-
Free-Float 94.83%
More Fundamentals * Assessed data

Chart Aelis Farma

Dynamic Chart

Latest news about Aelis Farma

Aelis Farma SA Announces the Last Patient, Last Visit in its Clinical Phase 2b Trial with AEF0117 for the Treatment of Cannabis Use Disorder CI
Aelis Farma SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Aelis Farma Appoints Chief Corporate Development Officer MT
Aelis Farma Announces the Appointment of Arsène Guekam as Chief Corporate Development Officer CI
Aelis Farma Announces Completion of Patient Randomization for Phase 2B Study with Aef0117 for the Treatment of Cannabis Addiction CI
Aelis Farma Announces Positive Results of Non-Clinical Studies Required by Regulatory Agencies to Enter Its First Cb1-SSI, AEF0117, in Phase 3 Clinical Trial for the Treatment of Cannabis Use Disorder CI
Aelis Farma SA Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Aelis Farma: CEO and co-founder recognized by his peers CF
Data Safety Monitoring Board OKs Aelis Farma's Mid-stage Trial of Cannabis Addiction Drug MT
Aelis Farma: received a positive opinion from the DSMB CF
Aelis Farma Receives a Positive Recommendation From the DSMB to Continue, With No Modification to the Protocol, the Phase 2b Clinical Study With AEF0117 in Cannabis Addiction CI
Aelis Farma: favorable preclinical data in autism CF
Aelis Farma Announces the Presentation of New Preclinical Data on its Drug Candidate AEF0217 at the 2nd European Conference on Phelan-McDermid Syndrome CI
CAC40: ends in green, ignores eurozone recession CF
Aelis Farma: promising results for AEF0117 CF
More news

Analyst Recommendations on Aelis Farma

AELIS FARMA : Degroof Petercam initiates buy coverage CF
More recommendations

Press releases Aelis Farma

Aelis Farma: Availability of the 2023 Universal Registration Document BU
Aelis Farma Announces the Last Patient, Last Visit in its Clinical Phase 2b Trial with AEF0117 for the Treatment of Cannabis Use Disorder BU
Aelis Farma Reports Its 2023 Annual Financial Resultsand Confirms Its 2024 Outlook BU
Aelis Farma : Inside Information / Other news releases PU
Aelis Farma announces its 2023 financial calendar AQ
More press releases

News in other languages on Aelis Farma

Aelis Farma : Mise à disposition du Document d’Enregistrement Universel 2023
Aelis Farma : Approbation AMF CP. R240004
Aelis Farma : Statuts de la Société (Mis à jour le 23 Janvier 2024)
Les nuages s'amoncellent sur les marchés
En Direct des Marchés : Schneider, L'Oréal, EssilorLuxottica, Sodexo, Believe, TSMC, Netflix...
More news

Quotes and Performance

1 day+0.77%
Current month+1.16%
1 month+0.77%
3 months-2.96%
6 months-2.96%
More quotes

Highs and lows

1 week
13.00
Extreme 13
13.20
1 month
12.80
Extreme 12.8
13.20
Current year
12.80
Extreme 12.8
13.60
1 year
12.80
Extreme 12.8
14.10
3 years
8.56
Extreme 8.56
14.48
5 years
8.56
Extreme 8.56
14.48
10 years
8.56
Extreme 8.56
14.48
More quotes

Managers and Directors - Aelis Farma

Managers TitleAgeSince
Pier Vincenzo Piazza FOU
 Founder 63 06/10/13
Marie Line Lefevre DFI
 Director of Finance/CFO - -
Helle Mengel CTO
 Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Anders Gersel Pedersen CHM
 Chairman 73 31/12/19
François Thomas BRD
 Director/Board Member 66 31/12/21
Irina Staatz-Granzer BRD
 Director/Board Member 63 31/12/21
More insiders

Quotes

Date Price Change Volume
29/04/24 13.1 +0.77% 59
26/04/24 13 0.00% 32
25/04/24 13 0.00% 101
24/04/24 13 0.00% 340
23/04/24 13 -0.76% 390

Real-time Euronext Paris, April 29, 2024 at 12:03 pm

More quotes

Company Profile

Aelis Farma is specialized in the research and development of drugs for the treatment of major disorders of the Central Nervous System (CNS). The company has 2 products in clinical development, including AEF0117 for cannabis-related disorders (severe dependence, acute psychosis and acute toxicity), and AEF0217 for cognitive deficits (disorders related to Down syndrome, Fragile X syndrome, Subjective Memory Impairment (SMI) and Alzheimer's disease).
Sector
Pharmaceuticals
Calendar
03/06/2024 - Annual General Meeting
More about the company

Income Statement Evolution

More financial data

Ratings for Aelis Farma

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
13 EUR
Average target price
20.67 EUR
Spread / Average Target
+58.97%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
AELIS FARMA Stock Aelis Farma
0.00% 182M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.86% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.78% 231B
NOVARTIS AG Stock Novartis AG
+5.23% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-8.75% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. AELIS Stock